A share price of Replimune Group Inc [REPL] is currently trading at $10.39, up 11.24%. An important factor to consider is whether the stock is rising or falling in short-term value. The REPL shares have gain 13.55% over the last week, with a monthly amount glided 0.10%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, ROTH MKM started tracking the stock with Buy rating on August 28, 2024, and set its price target to $17. Piper Sandler started tracking the stock assigning a Overweight rating and suggested a price target of $52 on November 19, 2021. BTIG Research started tracking with a Buy rating for this stock on November 17, 2020, and assigned it a price target of $60. In a note dated November 02, 2020, Jefferies initiated an Buy rating and provided a target price of $67 on this stock.
Replimune Group Inc experienced fluctuations in its stock price throughout the past year between $6.44 and $17.00. Currently, Wall Street analysts expect the stock to reach $27 within the next 12 months. Replimune Group Inc [NASDAQ: REPL] shares were valued at $10.39 at the most recent close of the market. An investor can expect a potential return of 159.87% based on the average REPL price forecast.
Analyzing the REPL fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.45, Equity is -0.58 and Total Capital is -0.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.72 points at the first support level, and at 9.06 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.73, and for the 2nd resistance point, it is at 11.08.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Replimune Group Inc [NASDAQ:REPL] is 7.95. On the other hand, the Quick Ratio is 7.95.
Transactions by insiders
Recent insider trading involved Astley-Sparke Philip, Director, that happened on May 20 ’25 when 32279.0 shares were sold. Chief Medical Officer, Xynos Konstantinos completed a deal on May 20 ’25 to sell 7952.0 shares. Meanwhile, Chief Accounting Officer Schwendenman Andrew sold 3287.0 shares on May 20 ’25.
